Investigational drug · Phase 2
CSL889
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sickle Cell Disease Vaso-occlusive Crisis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "CSL889"
First trial start
2025
Jul 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CSL889", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sickle Cell Disease Vaso-occlusive Crisis
Approved drugs for the same conditions: Sickle cell disease · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "CSL889" as an intervention, largest first.
CSL BehringIndustry
NCT06699849 · 70 participants (planned) · Start Jul 10, 2025 · Primary completion Oct 22, 2027
Drug: CSL889; Placebo · For: Sickle Cell Disease Vaso-occlusive Crisis
Sites: Oakland, California; Orange, California; Washington D.C., District of Columbia · 30 sites in all
CSL BehringIndustry
NCT04285827 · 28 participants · Start May 20, 2021 · Primary completion Jul 24, 2023
Drug: CSL889 · For: Sickle Cell Disease
Sites: Chicago, Illinois; Baltimore, Maryland; Minneapolis, Minnesota · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemia.
Biemond BJ, Kesse-Adu R, Wahab E, et al. · Haematologica 2026
- Acute therapy with hemopexin (CSL889) resolves LPS-induced lung vaso-occlusion in sickle mice.
Dubey RK, Vats R, Gentinetta T, et al. · Blood Vessel Thromb Hemost 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.